IQV vs SOPH: fair value comparison
IQVIA Holdings Inc. and SOPHiA GENETICS SA · Updated 2026-10-19
SOPH has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, IQV currently ranks higher by quality score.
| IQV | SOPH | |
|---|---|---|
| Verdict | Fairly valued | No estimate yet |
| Last price | $259.88 | $6.73 |
| 12-month range | $156.66–$275.02 | $3.89–$8.92 |
| Rank by discount to fair value | #51 of 108 Healthcare | — |
| Rank by quality score | #158 of 301 Healthcare | #160 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | High | Moderate |
| Margin trend | Contracting | Contracting |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | — | Mixed |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: IQV fair value analysis · SOPH fair value analysis